COX-2 Backlash? Fewer First-Cycle Approvals Would Signal Tougher FDA
Executive Summary
A first-cycle drug approval rate significantly lower than 40% could provide the first sign of an effect of COX-2 inhibitor safety issues on FDA reviews, a report from the contract research organization Parexel states
You may also be interested in...
First Cycle Approval Rate Tops 50% For 2006 NMEs; Merck Hits 100%
Merck skillfully navigated FDA's approval process in 2006, receiving all five of its new molecular entity and novel biologic approvals after only a single review cycle
First Cycle Approval Rate Tops 50% For 2006 NMEs; Merck Hits 100%
Merck skillfully navigated FDA's approval process in 2006, receiving all five of its new molecular entity and novel biologic approvals after only a single review cycle
FDA Personnel Moves Signal Continuity Under Commissioner Crawford
Five top-level FDA personnel appointments implemented July 29 suggest general agency policy will likely go unchanged in the near future